Background. Health economic modeling has paid limited attention to the effects that patients' psychological characteristics have on the effectiveness of treatments. This case study tests 1) the feasibility of incorporating psychological prediction models of treatment response within an economic model of type 1 diabetes, 2) the potential value of providing treatment to a subgroup of patients, and 3) the cost-effectiveness of providing treatment to a subgroup of responders defined using 5 different algorithms. Methods. Multiple linear regressions were used to investigate relationships between patients' psychological characteristics and treatment effectiveness. Two psychological prediction models were integrated with a patient-level simulation model of type 1 diabetes. Expected value of individualized care analysis was undertaken. Five different algorithms were used to provide treatment to a subgroup of predicted responders. A cost-effectiveness analysis compared using the algorithms to providing treatment to all patients. Results. The psychological prediction models had low predictive power for treatment effectiveness. Expected value of individualized care results suggested that targeting education at responders could be of value. The cost-effectiveness analysis suggested, for all 5 algorithms, that providing structured education to a subgroup of predicted responders would not be cost-effective. Limitations. The psychological prediction models tested did not have sufficient predictive power to make targeting treatment costeffective. The psychological prediction models are simple linear models of psychological behavior. Collection of data on additional covariates could potentially increase statistical power. Conclusions. By collecting data on psychological variables before an intervention, we can construct predictive models of treatment response to interventions. These predictive models can be incorporated into health economic models to investigate more complex service delivery and reimbursement strategies. Key words: cost utility analysis; decision analysis; simulation methods; logistic regression models. (Med Decis Making 2015; 35:872-887) H ealth economic modeling has largely ignored the effect that patients' individual psychological, social, and behavioral characteristics can have on the effectiveness of a treatment. In their expected value of individualized care framework, Basu and Meltzer 1 suggest that failing to base treatment decisions on individual characteristics may lead to poorer outcomes than taking a more individualized approach to clinical decision making. They recommend collection of data on heterogeneous parameters that are expected to influence treatment outcomes and incorporation of these into economic analyses to estimate the cost-effectiveness of treatments for individual patients. 1 Accounting for individually determined differences in treatment response could broaden the possible treatment options that could be evaluated in economic models. For example, subgroups defined by psychological characteristics, for which a treatment should or should not be provided, could be identified. This could lead to improvements in overall outcomes and cost-effectiveness.
Patient psychology and behavior are central to the management of diabetes, particularly treatment of type 1 diabetes. 2 Diabetes patients' individual characteristics have a major impact on their self-care health behaviors, for example, insulin injection and blood glucose monitoring, which are demanding and complex. 3 These health behaviors in turn affect HbA 1c , the key clinical measure of glycemic control. A reduction in HbA 1c of 0.5% has previously been reported as a clinically significant improvement for patients with diabetes. 4 Published economic models of diabetes such as the Centre for Outcomes Research (CORE) model, 5 the United Kingdom Prospective Diabetes Study (UKPDS) model 6 (a model of type 2 diabetes), the Economic Assessment of Glycemic control and Long-term Effects of diabetes (EAGLE) model, 7 and others [8] [9] [10] [11] do not currently account for psychological factors that may determine self-care behaviors and hence treatment outcomes. The aims of the current study were to test the feasibility of incorporating psychological prediction models of treatment response within an economic model of a type 1 diabetes structured education program, conduct an expected value of individualized care analysis to examine the potential value of providing treatment to a subgroup of patients, and investigate the cost-effectiveness of providing treatment to a subgroup of responders defined using 5 different treatment allocation algorithms.
METHODS

Case Description
The Dose Adjustment for Normal Eating (DAFNE) case study presented here provides a real-world example of heterogeneous treatment outcomes and how they can be incorporated within a health economic individual patient-level simulation model. DAFNE is a 5-day structured education program with a 6-week booster session, aiming to improve patients' self-care behaviors and glycemic control for adults with type 1 diabetes. DAFNE promotes flexible, intensive insulin therapy with a focus on adjusting insulin doses to match carbohydrate intake to allow greater dietary freedom. In 2002, the DAFNE Study Group published the results of a randomized controlled trial that suggested DAFNE improves (i.e., reduces) HbA 1c compared with no structured education. 12 More recent evidence shows that patients have heterogeneous response to DAFNE in terms of biomedical outcomes. Some patients experience significant HbA 1c reductions, whereas others exhibit no change or fail to maintain the original level of HbA 1c benefit over the long term (DAFNE Study Group, personal communication, 2006). 12, 13 The published cost-effectiveness analysis of the original DAFNE trial did not account for psychological factors and assumed that treatment response to DAFNE was homogeneous. 8 This study found that providing DAFNE treatment to all patients dominated providing DAFNE treatment to no patients (i.e., DAFNE produced more quality-adjusted life years [QALYs] at a lower cost). 8 Current clinical practice in the United Kingdom, as recommended in National Institute for Health and Care Excellence (NICE) guidance, is to provide a structured education program to all adults who have been diagnosed with type 1 diabetes. 14 
The Cost-effectiveness Model
The Sheffield Type 1 Diabetes Policy Model, hereafter the model, was developed as part of the National Institute for Health Research (NIHR) DAFNE research program following a detailed review of existing models, structured conceptual modeling, and workshops with UK clinical and evidence experts. 15 The model is an individual patient-level simulation model that covers all the major diabetic complications (neuropathy, nephropathy, retinopathy, cardiovascular disease, stroke) and acute events (severe hypoglycemia and diabetic ketoacidosis [DKA]) experienced by a population with type 1 diabetes. 16 More detail on the cost-effectiveness model inputs (risk equations, utilities, and costs) and the model process is reported elsewhere. 15 In brief, the model simulates individual patients and their annual progression through increasingly severe health states representing the diabetic complications. Patients remain in the model until death. Costs and utilities are attached to the events and health states in the model and are used to estimate costs and QALYs over a lifetime time horizon. The model takes a UK National Health Service (NHS) perspective, with all costs and QALYs discounted at a rate of 3.5%, as recommended by NICE. 17 The model has the capacity to model heterogeneous HbA 1c treatment response based on individual characteristics. This contrasts with assuming a homogeneous single average HbA 1c change for all patients in a treatment cohort as used in many previously published models. [7] [8] [9] The model uses a regression equation that predicts expected 12-month HbA 1c response conditional on each patient's individual characteristics. A random sample from the regression error term is added to each patient's expected 12month HbA 1c response, giving each patient an individual 12-month HbA 1c response. This development to the model reflects observations that some patients may experience a large reduction (improvement) in HbA 1c after undertaking the DAFNE course, whereas others may experience only a small reduction or even an increase in HbA 1c . Another key component of the model is that it also simulates the occurrence of DKA and severe hypoglycemic events as a function of whether a patient has received DAFNE and his or her HbA 1c , rather than as a fixed probability or a function of HbA 1c only.
In all analyses using the model, the individual 12month HbA 1c effect was assumed to be maintained for 4 years, after which patients return to their baseline HbA 1c level. 13 Any patients not receiving DAFNE were assumed to have their 12-month HbA 1c effect estimated using a linear regression based on the 6month follow-up of the patients allocated to the control arm in the original DAFNE trial. 12 Follow-up data from a later time point in the original DAFNE trial were not available, because all patients in the comparator arm of the trial attended the DAFNE course 6 months after randomization.
Data Sources
Two key data sources that form part of the NIHR DAFNE research program were used in the current study: a psychological data set and a clinical research database. The NIHR research program included a psychological questionnaire study to investigate psychological predictors of outcomes after DAFNE. 18 Ten psychological questionnaires were administered to 262 patients at baseline and at 3, 6, and 12 months post-DAFNE. Details of the questionnaires are presented in Table 1 . The following clinical and demographic data were also collected from the same participants (n = 262): In addition, the clinical research database collected clinical and demographic data from 1069 patients at baseline and 456 patients 12 months post-DAFNE. Variables collected in the research database that were not included in the psychological study were clinical risk factors (smoking status, blood pressure, cholesterol, triglycerides), treatment regimens (insulin type, insulin dose, pump use, other medication use), presence of diabetic complications, diabetes-related health care contacts and inpatient episodes, incidence of severe hypoglycemia, and hypoglycemia unawareness. The clinical research database was used to inform the cost-effectiveness model but was not used for the psychological prediction modeling.
The modeled patient cohort was constructed by randomly selecting, with replacement, patients from the psychological study sample to create a cohort of 5000 simulated patients. 19 Patient characteristics were augmented with data from the clinical research database and/or imputation where data were missing from the psychological data set. The baseline patient characteristics of the modelled cohort are presented in Table 2 .
Statistical Analysis of Psychological Data Set
Previous research has not reached a consensus on the appropriate conceptual framework for defining the relationships between psychological factors and clinical outcomes in diabetes. Studies report conflicting evidence about which psychological factors are and are not influential on glycemic control. [20] [21] [22] [23] [24] [25] [26] In the absence of a consensus, the current study assumed that all baseline psychological factors collected in the NIHR questionnaire study were potential predictors of HbA 1c change and that the possible effects of the factors were independent of one another, although interactions were tested. This assumption supported the use of regression techniques, which are the standard statistical approach to predicting an outcome for given inputs. 27 HbA 1c change from baseline to 12 months was selected as the measure of treatment response, with lower 12-month HbA 1c values representing a more favorable outcome. Two different definitions of HbA 1c change were used as dependent variables to produce 2 psychological prediction models of treatment response:
Model A: 12-month HbA 1c level measured on a continuous scale Model B: absolute change in HbA 1c from baseline to 12 months on a continuous scale Baseline summary scores from each psychological questionnaire in Table 1 and demographic variables were used as potential predictor variables for all analyses. Ordinary least squares regressions were used to investigate both predictors of treatment response. For both analyses, each potential predictor variable was first entered into a univariate model to examine its independent relationship with the HbA 1c change outcome. Those variables found to be significant univariate predictors of outcome (P \ 0.05) were then combined in a multivariate model, the interactions between these variables were tested, and variables were dropped that did not remain significant at the P \ 0.05 level in the multivariate model. Baseline HbA 1c was included as a predictor variable in model A where 12-month HbA 1c was used as the outcome variable. Baseline HbA 1c was not included as a predictor variable in model B, where change in HbA 1c was used as the outcome variable, as adjusting for baseline values when analyzing change scores has been shown to produce spurious results. 28, 29 Scatterplots of residuals from both linear models were examined for normality and homoscedasticity. SPSS Statistics 19 (SPSS, Inc., an IBM Company, Chicago, IL) was used to conduct the statistical analysis.
Expected Value of Individualized Care
To estimate the maximum value of making patientlevel rather than population-level decisions, we conducted an expected value of individualized care (EVIC) analysis. This analysis can be used to assess whether it is potentially valuable to implement a treatment allocation algorithm, which will assign patients to receive treatment if they are predicted to respond to it. EVIC is calculated by subtracting the average net monetary benefit (NMB) that would have been gained from making a population-level decision from the average NMB that could be gained if the treatment decision was made at the patient level. 1 In this case, an EVIC analysis calculates the maximum investment that can be made to perfectly individualize the decision to provide DAFNE treatment. 30 Therefore, it indicates whether stratification of DAFNE treatment using a treatment allocation algorithm is potentially worthwhile. To calculate EVIC, we conducted a cost-effectiveness analysis comparing DAFNE for all patients to DAFNE for no patients. There are 2 methods for calculating the EVIC; it can be calculated with or without cost internalization. The difference between the 2 methods is that when deciding between treatments at the individual level, the EVIC with cost internalization assigns each patient his or her cost-effective treatment option, whereas the EVIC without cost internalization assigns each patient his or her health maximizing treatment option. 1 In our implementation here, the EVIC with cost internalization has been used throughout as it is consistent with the UK NHS perspective. As there are 2 psychological prediction models for the 12-month HbA 1c effect of DAFNE, 2 EVIC analyses were conducted.
Cost-effectiveness Analyses
Cost-effectiveness analyses compared using 5 treatment allocation algorithms to providing DAFNE to all patients, which is current practice in the United Kingdom. 14 The treatment allocation algorithms compared each patient's predicted change in HbA 1c with a defined change in HbA 1c cutoff value. Patients with a predicted change in HbA 1c below the cutoff value were defined as predicted responders; otherwise, the patients were defined as predicted nonresponders. All treatment allocation algorithms assign the predicted responders to receive DAFNE and predicted nonresponders to not receive DAFNE. The 5 HbA 1c cutoff values to be used in the treatment . It is expected that as the reduction in HbA 1c needed to define a patient as a responder is reduced, more patients would be predicted to be a responder. These potential new strategies were selected for evaluation because cost savings might be made by not referring patients for DAFNE training if they were unlikely to experience HbA 1c benefit.
Sensitivity Analyses
Five hundred probabilistic sensitivity analysis (PSA) runs, each with 5000 patients, was conducted in all analyses. This ensured that parameter uncertainty was taken into account in the expected costs and QALYs. Structural uncertainty was explored by testing how sensitive the cost-effectiveness results were to the use of either model A or model B as psychological prediction models of HbA 1c response to DAFNE.
RESULTS
Psychological Prediction Model Results
The 2 psychological prediction models produced differing results, as shown in Table 3 . Psychological prediction model A suggested that baseline HbA 1c and fear of hypoglycemia were predictive of 12month HbA 1c . The adjusted R 2 suggested that this model explained 53.4% of the variance in 12-month HbA 1c . Patients with higher baseline HbA 1c and higher baseline fear of hypoglycemia were predicted to have higher 12-month HbA 1c . This appears in line with expectations because patients afraid of hypoglycemia may be reluctant to apply the DAFNE principles, which aim to reduce HbA 1c due to concerns that adjusting their insulin dosage may lead to hypoglycemia. The model correctly categorized 87.3% of nonresponders but only 31.9% of responders.
Psychological prediction model B suggested that BMI, sex, and baseline fear of hypoglycemia were predictive of change in HbA 1c from baseline to 12 months. The fear of hypoglycemia results corresponded with those of prediction model A. The results also suggested that male patients and patients with higher BMI were more likely to experience an improvement in HbA 1c . The adjusted R 2 suggested that this prediction model explained 5.4% of the variance in change in HbA 1c . The model correctly categorized 90% of nonresponders but only 16.5% of responders.
A comparison of the sensitivity and specificity of each psychological prediction model is presented in Table 4 . Both models were better at predicting nonresponders than responders. Figure 1 presents a further comparison of the models' predictive power. For each model, the observed change in HbA 1c from baseline to 12 months is plotted against the expected change. This figure confirms that both models were better at predicting nonresponders than responders. Figure 2i shows the cost-effectiveness plane for the comparison of DAFNE for all v. DAFNE for none The first thing to note is that the position of the mean shows that, for both prediction models, the policy of offering DAFNE to all patients compared with the policy of not offering DAFNE to all patients generated on average more QALYs (model A: 0.0898; model B: 0.0519) for lower costs (model A: -£2358; model B: -£1578), suggesting that offering DAFNE to all patients dominated offering DAFNE to no patients.
EVIC Results
The second key point is that the PSA results suggest that this conclusion is relatively certain. Figure  2ii presents the cost-effectiveness acceptability curve for providing DAFNE to all patients and the expected value of perfect information (EVPI) per patient. At a cost-effectiveness threshold of £20,000 per QALY, DAFNE has a greater than 90% probability of being cost-effective for the whole population (model A: 98.6%; model B: 92.0%). The EVPI per patient was £6.18 and £63.48 for prediction models A and B, respectively. This indicates the decision to provide DAFNE to all patients (compared with DAFNE for none) is likely to be insensitive to plausible parameter variation.
However, it is the third key issue, that of individuallevel heterogeneity, that is the real focus of EVIC analysis. DAFNE was more costly for a minority of patients (model A: 29.1%; model B: 32.1%) and was more effective for a majority of patients (model A: 64.2%; model B: 59.2%). More important, based on a costeffectiveness threshold of £20,000 per QALY, DAFNE is cost-effective for most patients (model A: 72.8%; model B: 67.4%). This can be seen in Figure 2i , in that around 70% of the simulated patients (light gray dot) are to the right of and below the cost-effectiveness threshold line. An EVIC calculation is essentially a thought experiment, which goes through the following steps: first, imagine that we had some way of preidentifying the precise future outcome for each individual; second, imagine instead of giving the treatment to all people, we would give it to those who would ''benefit'' from it (in our analysis, that would be those who turn out to be right and below the costeffectiveness line); and then third, what would be the overall resulting costs, QALYs, and NMB of such a perfectly accurate individualized care strategy compared with our baseline adoption decision of giving DAFNE to all patients.
When applying this process to our case study, the resulting EVIC per patient was a net monetary benefit of £1016 and £1568 for prediction models A and B, respectively, at a cost-effectiveness threshold of £20,000 per QALY. This is equivalent to a net QALY gain per person of 0.0508 or 0.0708, respectively. In the context of an intervention where the estimated mean QALY difference between a DAFNE for all strategy and a DAFNE for no strategy is 0.0898 (model A) and 0.0519 (model B), it can be seen that these EVIC values can be considered substantial. Figure 2iii presents the individual costeffectiveness acceptability curve and the EVIC per patient at a range of different threshold values. This supports the testing of treatment allocation algorithms for patients considered eligible to receive DAFNE.
Cost-effectiveness Results
The cost-effectiveness analysis suggested that the new policy of using the treatment allocation algorithm would not be cost-effective and indeed would be dominated by the current practice of offering DAFNE to all patients. Detailed results from the cost-effectiveness analysis for giving DAFNE only to predicted responders as defined using the HbA 1c cutoff value of 20.5% are presented in Table 5 . We present the detailed results for this cutoff value, because it has previously been reported as a clinically significant change in HbA 1c for patients with diabetes. 4 For both psychological prediction models, the new policy generated fewer QALYs (model A: -0.05; Figure 3 . The mean effect and the majority of PSA runs lie in the northwest quadrant of the cost-effectiveness plane for both prediction models. This indicates that DAFNE for all dominates using this treatment allocation algorithm for this HbA 1c cutoff value. The results of the other HbA 1c cutoff values used to define a patient as a responder or nonresponder in the treatment allocation algorithm are presented in Table  6 . In all but one treatment allocation algorithm, the new policy of using the treatment allocation algorithm was dominated, generating fewer QALYs and higher costs than the current practice of DAFNE for all. In the scenario where prediction model B was used with an HbA 1c cutoff value of 0.1%, the treatment allocation algorithm was not dominated. Despite generating more QALYs, it had substantially higher costs and, with an incremental cost-effectiveness ratio (ICER) of approximately £71,000 per QALY gained, would still not be considered cost-effective against the upper range of the usual maximum acceptable ICER used by NICE of £30,000 per QALY. 17 This suggests that, even if the HbA 1c response subgroups are defined differently, the allocation of DAFNE to predicted responders on the basis of model A or model B is very unlikely to be cost-effective compared with the current practice of giving DAFNE to all.
DISCUSSION
This study used data on psychological variables collected before, during, and after an educational intervention for self-management of type 1 diabetes to produce estimates of predicted response in terms of the glucose control measure HbA 1c at the 12-month follow-up. We found that sex, fear of hypoglycemia, baseline HbA 1c , and BMI are predictive of response within 2 different psychological prediction models. The 2 prediction models are poor at correctly predicting responders but strong at correctly predicting nonresponders. The predictive models have then been used to derive a potential strategy for targeting the educational intervention just at those predicted to achieve response. A cost-effectiveness model has been adapted to analyze this targeted strategy. In this case study, the treatment allocation algorithms for targeting structured education were not cost-effective, as the prediction models did not have sufficient predictive power to detect patients who responded to DAFNE. However, in other cases, targeting treatment based on patients' psychological characteristics may be cost-effective.
The methods used to produce the psychological prediction models, which are used to predict response to DAFNE, have 4 important limitations. First, a priori hypotheses were not specified about the relationship between psychological variables and HbA 1c . It has been suggested that conducting this type of post hoc analysis is less likely to offer a reliable explanation of individual differences in treatment response. 31, 32 Nevertheless, the predictive factors found within the study have good face validity, and the psychological rationale for each appears plausible. Second, the data that were collected in the psychological study and therefore used in the statistical modeling were based on a conceptual model of the psychology of diabetes self-management proposed by the DAFNE psychology team rather than on a published theory of health behavior (although the conceptual model was informed by social cognition models and other published evidence [33] [34] [35] . The psychological prediction models tested had moderate predictive power of HbA 1c response to DAFNE, and this may have been limited because some of the predictors of DAFNE response were not collected or are not observable. Other variables such as personality factors 25, 36 or attitudes toward the DAFNE course 37 could have provided additional predictive power to the regression models. Combining more detailed information from future psychological questionnaire data collected from DAFNE graduates with published qualitative findings [38] [39] [40] would allow the psychological prediction models to be refined. A third limitation is the sample size of the psychological study, which may not have been large enough to detect some relationships between the collected psychological variables and HbA 1c response outcomes. Finally, the statistical analysis used simple linear regression to explore relationships. More advanced techniques such as latent class modeling or mixture modeling could potentially offer alternative analysis methodologies and may unearth predictive relationships between variables that were not identified by the current study. More advanced statistical modeling techniques could also have allowed the prediction of other outcomes of DAFNE such as change in the risk of severe hypoglycemia alongside prediction of HbA 1c change. An issue with the psychological prediction models is the somewhat different results produced by both models. Discussion in the psychological literature suggests that covariance-adjusted models (i.e., model A) are generally preferred to change score models (i.e., model B), although some have claimed otherwise. 41 Based on this literature and on the greater predictive power demonstrated by model A, we would suggest this model is to be preferred to model B.
If a psychological prediction model is potentially cost-effective, then it is important to account for the cost of eliciting information used to predict treatment benefits or costs. 1 A limitation of the current study is that we assumed that predictor variable data are collected at zero cost in the cost-effectiveness analysis. Background variables such as sex and BMI are likely to be routinely collected and therefore easily available. However, questionnaire variables such as fear of hypoglycemia and thoughts about diabetes seriousness would need additional data collection, which is not part of routine care. Normally, the cost of data collection would be estimated using either estimates of staff time and unit costs or a threshold analysis to identify the maximum cost of data collection at which the intervention is cost-effective. However, in the current study, the new intervention was found to be dominated by current practice even under the assumption that the additional data collection is cost free; therefore, additional estimates of data collection cost were unnecessary.
Another limitation of the current study is that only patient heterogeneity in treatment response was considered. Patient heterogeneity in other factors, such as baseline risk and treatment costs, was not considered. However, if information was available on these aspects of patient heterogeneity, it would be possible to incorporate these factors of patient heterogeneity into health economic models using similar methodologies to those used in the case study to incorporate patient heterogeneity in treatment response. It is important to acknowledge that ethical issues could be raised if a patient's psychological characteristics determined whether or not he or she received treatment. The analyses undertaken in economic analysis consider only the cost and health consequences of providing a treatment. Ethical input should be sought if treatment allocation algorithms, based on the patient's psychological characteristics, were to be adopted based on the results of an economic model.
The results of this study suggest that a new policy of offering DAFNE only to those patients who are predicted by psychological prediction models to respond would not be cost-effective compared with the current practice of offering DAFNE to everyone, because of the poor prediction of responders and the relatively low cost of DAFNE. No recommendations for changes to current practice are therefore indicated.
Further research could investigate collecting data directly, representing patients' behavioral response to an intervention (which may be a more accurate predictor of HbA 1c response than the cognitive psychological variables collected here) and incorporating patients' behavioral response into a health economic simulation model. However, as the behaviors promoted by DAFNE are highly complex, it would be a challenge to link a prediction model of self-care behavior to long-term outcomes within the model. This task would be considerably eased if there was a strong relationship between the measure of selfcare behaviors collected in the psychological questionnaire study 42 and HbA 1c change, which was not the case in the current study. A DAFNE-specific measure of self-care behaviors is currently under development and may prove to have a stronger relationship with HbA 1c outcomes, in which case further work could explore this method of predicting individual treatment response and incorporate it in cost-effectiveness modeling. Other variables that could provide additional predictive power to prediction models of treatment response could also be collected in future research.
The results of this study demonstrate that improvements can be made to the way we model the cost-effectiveness of interventions in disease areas where patients' psychological and behavioral characteristics are important. As Sculpher 32 posited, ''Appropriately reflecting subgroups and heterogeneity in decisions has the potential to increase population health gains.'' Modeling patients' psychological characteristics alongside their clinical characteristics has allowed heterogeneity in response to DAFNE 1 If a preexisting patient-level simulation model exists, conduct an EVIC analysis to explore the potential value in individualizing care. 2 If there is potential value in individualizing care, seek advice from multidisciplinary experts working in the disease area, including psychology researchers and clinicians. 3 Form a priori hypotheses regarding the relationships between psychological variables and treatment effectiveness. 4 Base hypotheses and analyses on psychological theories of health behavior or on published evidence regarding the relationships between psychological variables and treatment effectiveness. 5 Plan analysis of psychological data prior to data collection, at the conceptual modeling stage, for the new or revised health economic model to ensure all important variables for your analysis are collected. 6 Ensure sample size for the collection of psychological data is large enough to detect the hypothesized relationships by conducting sample size calculations. 7 Collect psychological data from the same patients for whom the clinical effectiveness data are collected, at the same time points as the clinical effectiveness data. 8 Test and validate any prediction models of treatment effectiveness against observed treatment response rates. 9 Develop a new or revised economic model to integrate psychological data. 10 Undertake health economic analyses of alternative options for stratifying the treatment based on the prediction models. 11 Account for the cost of collecting psychological predictor variables when comparing a potential treatment allocation algorithm to current care.
EVIC, expected value of individualized care.
to be reflected and linked back to underlying psychological factors that affect patients' propensity to benefit from the intervention. The implications of this methodology are that policy questions that could not be addressed using purely clinically driven cost-effectiveness models can now be explored. The method opens up the opportunity to ask, ''What types of patients will do well after DAFNE?'' ''For what types of patients is DAFNE more cost-effective?'' and ''What additional support needs to be provided for the potential nonresponders?'' The subgroups here are psychologically rather than clinically defined, and we may be able to improve the clinical and cost-effectiveness of DAFNE by ''treating'' psychological characteristics such as fear of hypoglycemia prior to patients' attendance at the DAFNE course. Potentially, there will be cost and health consequences from ''treating'' psychological characteristics. Where there are appropriate data, treating the psychological characteristics should be analyzed as a separate treatment option using the methods appropriate to the perspective taken in the analysis. Based on the experience of conducting this study, we have made 11 recommendations for researchers wishing to conduct further research using psychological data to inform cost-effectiveness models. These recommendations are presented in Table 7 and cover data collection strategies, project planning, data analysis methods, and suggestions for integrating the results of psychological data analysis with a costeffectiveness model. While our study and these recommendation focused on variability of individual response in the context of psychological factors, the recommendations made in Table 7 may still be useful when incorporating psychological data analysis on other aspects of patient heterogeneity, such as heterogeneous baseline risk of events or heterogeneous costs into a cost-effectiveness model.
We conclude that none of the 5 treatment allocation algorithms for allocating DANFE to predicted responders appear to be cost-effective compared with DAFNE for all patients. The framework that we have developed to incorporate psychological predictors of treatment response into a cost-effectiveness model can be generalized for use in other case studies where psychological or other predictors of individual response are available. The prior use of EVIC analysis can be useful to identify case studies where the use of treatment allocation algorithms might be cost-effective. Patients experience heterogeneous responses to health care interventions, and it is an oversimplification to assume that this heterogeneity is not, at least in part, due to differences in patients' psychological characteristics. Accounting for these differences within a cost-effectiveness model is both feasible and relatively simple if the appropriate data are collected alongside clinical outcomes. We hope that our experience and our recommendations will aid researchers wishing to incorporate psychological predictors of treatment response into their own cost-effectiveness models.
